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A physician targeted intervention improves
prescribing in chronic heart failure in
general medical units
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Craig Aboltins1,4
Abstract
Background: Despite strong evidence for beta-blockers and angiotensin-converting enzyme inhibitors (ACEI) or
angiotensin receptor blockers (ARB) in chronic heart failure (CHF), they have been under-utilised especially in general
medical units. We aim to evaluate the effectiveness and feasibility of a physician-targeted quality improvement
intervention with education and feedback on the prescription of beta-blockers and ACEI/ARB for CHF management in
an inpatient setting.
Methods: We conducted an interrupted time series study between January 2009 and February 2012. A two-stage
intervention was implemented. Between November 2009 and January 2011, a structured physician-oriented education
program was undertaken. From February 2011, quarterly performance feedback was provided to each medical unit by
a senior clinician. Medical notes of patients admitted with CHF under general medical units before and during the
intervention were prospectively audited. Main outcomes were beta-blockers and ACEI/ARB prescription rates, and 180-
day readmission rates for CHF.
Results: Four hundred and sixty-eight patients were included in this study. Structured education program was
associated with a significant rise in beta-blockers prescription rates from a baseline of 60 to 92% (p = 0.003), but a non-
sustained rise in ACEI/ARB prescription. Regular performance feedback resulted in a further sustained increase in ACEI/
ARB prescription rates from 62 to 93% (p = 0.028) and a positive trend for beta-blockers with rates maintained at 89%.
There was a reduction in 180-day readmission rates that correlated with the improvements in beta-blocker (p = 0.030)
and ACEI/ARB (p = 0.035) prescription.
Conclusion: Implementation of a structured education program with regular performance feedback was durable and
was associated with improvements in appropriate prescribing and an observed decrease in CHF-related readmissions.
Keywords: Chronic heart failure, Quality improvement, Health professions education, Audit and feedback, Hospital
medicine
Background
Exacerbation of chronic heart failure (CHF) is a leading
cause of hospitalisation worldwide. CHF is estimated to
cost more than $1 billion per year in Australia and
more than $34 billion per year in the United States of
America (USA), with hospitalisation accounting for
two-thirds of the total expenditure [1–3]. Prevalence of
CHF in the Australian, European and USA population
is approximately 6.5% in ages 60 and over, rising expo-
nentially in older age groups [4].
There is compelling evidence that the use of certain beta-
blockers and an angiotensin-converting enzyme inhibitor
(ACEI) or angiotensin receptor blocker (ARB) can alleviate
symptoms, reduce hospitalisations and extend the survival
of patients with CHF [5, 6]. International CHF manage-
ment guidelines strongly recommend using these medica-
tions as first-line therapy in patients with CHF [7–9].
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Multiple studies have observed underutilisation of these
medications in patients hospitalised for exacerbation of
CHF, especially among general medical units. Prescription
rates for ACEI or ARB have been reported to be between
58.7 to 89.2%, and beta-blockers between 10.4 and 80.1%
for hospitalised patients with CHF [10–14]. In-hospital
initiation of medical therapy has been associated with
higher continuation rates post discharge [15].
Translating clinical guidelines to clinical practice is
challenging. Multiple methods have been used to change
physicians’ practices: audit and feedback, reminders,
education, local consensus processes, financial incentives
and financial penalties [16]. Systematic reviews have re-
ported that multifaceted interventions with a combin-
ation of two or more strategies are more consistent in
promoting behavioural change among health profes-
sionals [17].
This study aims to report the effectiveness of structured
education, audit and feedback as a quality improvement
initiative targeted at physicians on the prescription of
evidence-based medications in CHF management in
general medical units of an outer metropolitan teaching
hospital.
Methods
Study design and setting
This was an interrupted time series study conducted be-
tween January 2009 and February 2012 at The Northern
Hospital, a 320 bed outer metropolitan public teaching hos-
pital catering to a community of approximately 728,000
people in North of Melbourne, Victoria, Australia. There
were six general medical units during our study period.
Quality improvement intervention
A two-stage intervention targeting all physicians and
junior medical doctors in general medical units was
implemented.
Stage one
Stage one focused on structured education program and
dissemination of CHF management guidelines involving
physicians and junior doctors at all levels of training. A
hospital-based CHF management guideline was developed
with emphasis on two key performance measures: 1) pre-
scribing evidence-based beta-blockers, 2) prescribing
ACEI or ARB. A senior physician presented the guideline
regularly during medical grand rounds and doctors’ edu-
cation sessions in the allocated period. Printed materials
such as posters and policies were distributed around the
hospital.
Stage two
Rates of prescription of beta-blockers and ACEI/ARB
for patients under each general medical unit was audited
and fed back to each unit. Feedback of audit results was
provided quarterly to doctors of each general medical
unit by a senior physician in both written and verbal for-
mat. The audit results were also made available to all
medical units, with results presented regularly in the
broader general medical unit meetings. The average
beta-blocker and ACEI/ARB prescription rates across all
medical units were provided for benchmarking.
There was no specific intervention by researchers in
the management of individual patients and individual
patient level data was not routinely made available to
doctors.
Data collection
Patients were eligible for auditing if they were dis-
charged alive from a general medical unit with a primary
diagnosis of heart failure. This was defined as a Inter-
national classification of diseases 10th Revision (ICD-10)
diagnostic-related group (DRG) code of F62A (heart fail-
ure with catastrophic complications) or F62B (heart fail-
ure without catastrophic complications). The term
‘catastrophic complications’ relate to the amount of re-
sources used during that episode as determined by a na-
tionwide standardised case complexity matrix. The use
of ICD-10 codes for case identification was a reliable
method as it was compulsory for every patient to have a
discharge summary that was coded with ICD-10 codes
to ensure appropriate assignment of DRG, which im-
pacted on funding allocation to the hospital. Patients
were excluded from the audit if they were under 18 years
of age, did not require an inpatient admission, managed
by another specialty medical team within the health ser-
vice or died during that admission. The health service
administrative dataset was used prospectively to identify
all potential eligible cases. We audited every second eli-
gible patient with a minimum target of five patients per
general medical unit per month. If less than five patients
were discharged from a general medical unit in a par-
ticular month, all eligible patients from that unit were
audited.
Researchers reviewed the discharge prescriptions and
recorded the use of evidence-based beta-blockers, ACEI
or ARB. The beta-blockers deemed appropriate for use
were metoprolol succinate, carvedilol and bisoprolol. Pa-
tients on nebivolol were not included in this study as the
evidence for nebivolol and its routine use was not avail-
able at the time of establishing the project protocol and
for the first half of the study period. The proportion of
patients prescribed each of the medication classes was
calculated as the percentage of potential eligible patients
for that treatment modality. If patients met exclusion
criteria for the use of beta-blockers (defined as medica-
tion allergy, asthma and second or third degree heart
block) or ACE/ARB (defined as medication allergy, ACEI
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related cough, acute kidney injury (defined as abrupt de-
cline in renal function with creatinine increasing to
more than 1.5× baseline), hyperkalaemia (exceeding
5.5 mmol/L) or bilateral renal artery stenosis), they were
excluded from the denominator for their respective
treatment modalities. Of note, the presence of an echo-
cardiogram result and documentation of left ventricular
dysfunction was not collected to use for feedback in
order to avoid pressure on hospital costs and access to
this limited resource.
Baseline data on prescription rates was collected from
January 2009 to October 2009. Stage one intervention
occurred between November 2009 and January 2011.
Stage two commenced in February 2011 and continued
through to February 2012.
Outcomes
The primary outcomes for this study were the proportion
of patients with a primary diagnosis of CHF who received
an evidence-based beta-blocker where there was no contra-
indication, and the proportion of patients who received an
ACEI/ARB where there was no contraindication.
Secondary outcome measure was the 180-day hospital
readmission rates for exacerbation of CHF for all pa-
tients in the dataset. Outcomes were collected on a
monthly basis from January 2009 to February 2012.
Statistical analysis
The trends of medication prescriptions were analysed
using interrupted time series analysis procedures. The
possibility of both an instantaneous shift and progressive
increasing or decreasing change in the medication pre-
scription rates per month following the introduction of
each stage of the interventions were assessed.
Using the Durbin-Watson statistic and by examining
auto-correlation it was determined that there was little
evidence of auto-correlation in the beta-blocker and
ACE/ARB data series. The trends in prescription rates
were generally stationary when taking into account shifts
after each intervention and seasonal components of the
series, thus only Auto-Regressive and Moving Average
(ARMA) processes were explored. Statistical analyses
were performed with Stata, version 12 (StataCorp, Col-
lege Station, Tex, USA), with a two-sided p-value of less
than 0.05 considered to indicate statistical significance.
Ethics
This project was registered with the Quality and Patient
Safety Unit at Northern Health as a quality improvement
(audit and feedback) activity and approved for publica-
tion by the Northern Health Low-Risk Research Ethics
committee.
Results
Between January 2009 and February 2012, a total of 847
patients were discharged from the general medical units
of The Northern Hospital with a primary diagnosis of
CHF exacerbation. Of which, we audited the medical re-
cords of 468 (55%) patients. The mean age of audited
patients was 78 (±10.4) years, with 52% of total patients
being female. Baseline characteristics of patients were
similar between the audited and non-audited groups
(Table 1). During the intervention period the mean quar-
terly discharge rate for patients with CHF was 88 pa-
tients, of these an average of 58 (66%) were included in
the audit each quarter.
Primary outcome
Overall, the prescription rates of both beta-blockers and
ACEI/ARB for patients discharged with a primary diag-
nosis of CHF improved throughout the study. Prescrip-
tion rates of beta-blockers and ACEI/ARB across the
intervention periods can be seen in Fig. 1. A summary of
results from time series analysis by intervention period
for beta-blockers and ACEI/ARB is shown in Table 2.
The use of beta-blockers rose significantly during stage
one of our intervention, with an average increase of 3.3%
per month (95%CI: 1.1% to 5.4%, p = 0.003) over the 15-
month period. The prescription rate for beta-blockers in-
creased from 60% before the intervention, to 92% at the
conclusion of stage one. Throughout stage two of our
intervention, there was no significant shift (p = 0.791) or
change to the underlying trend (p = 0.415) in the prescrip-
tion of beta-blockers with the rates stabilising to a range
of 87 to 89% over the remainder of the study period.
ACEI/ARB prescription rates had a significant initial
rise of 41.6% (95%CI: 24.4% to 58.6%, p < 0.001) from 53
to 94.6% at the start of stage one of the intervention, al-
though the impact was lagged by 1 month. Over the
Table 1 Baseline patient characteristics (N = 847)
Audited
(N = 468)
Not Audited
(N = 379)
Number of separations 664 560
Age, mean (SD) (years) 77.9 (±10.4) 77.7 (±10.2)
Female (%) 345 (52%) 308 (55%)
Severity of CHF based on DRG code
F62A 236 (36%) 202 (36%)
F62B 428 (64%) 358 (64%)
Discharge destination
Private residence 530 (80%) 421 (75%)
Aged care facility 34 (5%) 24 (4%)
Transfer to other healthcare facility 95 (14%) 67 (12%)
Abbreviations: SD standard deviation, CHF chronic heart failure, DRG
diagnostic-related group, F62A heart failure with catastrophic complications,
F62B heart failure without catastrophic complications
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Fig. 1 Observed rate and linear trends by intervention period for beta-blockers (top) or ACE/ARB (bottom) prescription
Table 2 Interrupted time series analysis by intervention period for the prescription rates of beta-blockers and ACEI/ARB
Beta-blockers ACEI/ARB
Percentage (%) 95% CI
(%)
p-value Percentage
(%)
95% CI
(%)
p-value
Baseline trend
Prescription rate at month zero 72.8 60.3 to 85.3 < 0.001 89.2 76.7 to 100 < 0.001
Monthly change in prescription rates −1.3 −3.3 to 0.7 0.198 −3.3 −5.2 to − 1.4 0.001
Stage one intervention
Initial shift in prescription rates due to
intervention (effects lagged by 1 month)
+ 2.2 − 11.3 to 15.8 0.747 + 41.6 24.4 to 58.6 < 0.001
Subsequent monthly change in prescription rates + 3.3 1.1 to 5.4 0.003 + 1.1 −1.4 to 3.6 0.377
Stage two intervention
Initial shift in prescription rates due to
intervention (effects lagged by 1 month)
−4.6 − 38.9 to 29.6 0.791 + 13.7 −7.8 to 35.1 0.213
Subsequent monthly change in prescription rates −1.8 −6.2% to 2.5% 0.415 + 3.6 0.4% to 6.9% 0.028
Abbreviations: CI confidence interval, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blocker
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remainder of stage one, the prescription rates for ACEI/
ARB reduced steadily to a level of 62%. In stage two, we
observed a significant sustained upward trend for ACEI/
ARB prescription rates at an average rate of 3.6% in-
crease per month (95%CI: 0.4% to 6.9%, p = 0.028), also
lagged by 1 month, with values reaching 93% by the con-
clusion of stage two.
Secondary outcome
As shown in Fig. 2, the average 180-day readmission rate
during the pre-intervention period was 3.5% and this
had reduced to 3.0% during Stage 2. Time series analysis
showed there was a significant negative correlation be-
tween 180-day readmission rates for CHF exacerbation
and prescription of beta-blocker (p = 0.030) and ACEI/
ARB (p = 0.035), with the 180-day readmission rate for
CHF reducing in the month following increases in the
prescription rates of beta-blockers and ACEI/ARB.
Discussion
This study examined the feasibility and durability of
implementing a structured education, audit and feedback
program on physicians’ prescribing behaviours in the in-
patient management of CHF in a real-world public hos-
pital. Our intervention was carried out over a 27-month
period to provide a realistic reflection of its applicability.
Overall, we have demonstrated that this combination of
quality improvement strategies was associated with signifi-
cant improvements in evidence-based medication use, and
may have lead to the observed reduction in the readmis-
sion rates for patients hospitalised for exacerbation of
CHF.
Studies have evaluated the use of CHF disease man-
agement programs or registries to improve the quality of
care in CHF patients [18–23]. Most programs adopt a
complex multidisciplinary approach involving a team of
different health care professionals with various combina-
tions of strategies such as clinical decision support tool-
kits, educational sessions, web-based benchmarked qual-
ity reports and provision of discharge instructions. The
Organized Program to Initiate Lifesaving Treatment in
Hospitalized Patients with Heart Failure (OPTIMIZE-
HF) registry reported an increase in beta-blocker use
from 76.5 to 86.4% and maintenance of ACEI/ARB use
at 75.8% in 259 hospitals after a 2-year intervention
period [22]. A lesser degree of improvement was noted
in an Australian CHF quality improvement program
where nine hospitals employed strategies that mainly in-
cluded a combination of clinical decision support tools
and education [24]. Beta-blockers prescription rates on
discharge rose from 34 to 52%, and ACEI/ARB rates sta-
bilized at 68% with no significant changes [24]. Although
physician education and feedback have constituted parts
of these previously published interventions, it has been
difficult to evaluate the relative impact of these interven-
tions on physician prescribing behaviour in CHF
management.
We observed that our first intervention with a struc-
tured education program resulted in significant increases
in prescriptions for beta-blockers and ACEI/ARB that
was sustained for beta-blockers but not ACEI/ARB. The
reason for this discrepancy is not immediately clear, but
possible explanations include concerns with medication
side effects such as hypotension or renal impairment.
The baseline ACEI/ARB prescription rates were also ob-
served to be higher than beta-blockers, which may have
accounted for the reduced impact of our first interven-
tion It may also reflect the inconsistent performance of
Fig. 2 Observed 180 day readmission rates in relation to prescription rates of beta-blockers and ACEI/ARB
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education and guideline dissemination as an interven-
tion in altering physician behaviour as shown in previous
studies [25–27]. Nevertheless, education sessions and
printed educational materials are often incorporated as
part of a more comprehensive approach in view of the
feasibility and relative low costs.
In theory, physicians perform better when their per-
formance is monitored regularly and feedback provided
with minimal delay to allow appropriate modification of
clinical practice [28]. This effect is further enhanced
when using achievable benchmarks by comparing their
results with their peers [29]. The findings in our study,
where audit and feedback of up-to-date information was
associated with a notable increase in evidence-based prac-
tice, confirm those of a recent Cochrane review that evalu-
ated the impact of audit and feedback in the management
of various conditions, not limited to CHF [30, 31]. They
concluded that audit and feedback could lead to important
improvements in clinical practice especially in physician
prescribing [30]. One of our main challenges included the
frequent turnover of junior medical staff in the institution
i.e. short rotations through general medicine. As such, the
delivery of regular and frequent feedback by senior med-
ical staff likely contributed to its effectiveness as an inter-
vention for improving prescription rates [31]. We also
hypothesise that the low baseline guideline adherence in
our study potentially contributed to the greater effect size
observed in our post-intervention prescription rates [30].
Following the implementation of our quality improve-
ment intervention, particularly in Stage 2, there is a not-
able reduction in the 180-day readmission rates for CHF
at our hospital that coincided with the increased pre-
scription of ACEI/ARB and beta-blockers. This is in line
with existing strong evidence demonstrating improve-
ments in this outcome [23, 32]. This observed outcome
is important as reduced readmission rates have a great
implication on the associated healthcare costs and would
justify this relatively low cost intervention. In addition,
the use of ACEI/ARB and beta-blockers has been shown
to reduce mortality in patients with CHF [5, 6]. How-
ever, this association was not observed as this study is
underpowered to detect changes in this outcome.
In order to reduce the impact on limited resources, we
did not mandate the demonstration of left ventricular dys-
function of patients for entry in to this study by echocardi-
ography or other methods. This is important as the
evidence of benefit from the assessed medications for pa-
tients with heart failure with preserved ejection fraction
(HFPEF) is less clear [33, 34]. Patients with HFPEF may
have accounted for up to 50% of our cohort and hence
would have potentially resulted in an underestimation of
the observed reduction in readmission rates. However, this
would not have changed the main aim of this study of
linking education and feedback to prescribing behaviours.
This study was conducted in a single hospital and the
impact of our intervention may not be generalised to
other hospitals due to the difference in processes of care
and organisational factors. We did not have a control
group, thus the improvements in care observed may re-
flect secular trends in care rather than direct effects of
our intervention. A control group was not established as
the Australian hospital system was such that junior doc-
tors frequently rotate through different general medical
units within the same hospital and may confound the re-
sults. Nonethless, utilising interrupted time-series analysis
as a statistical technique overcomes many of the limita-
tions of the lack of control group if using historical con-
trol. Moreover, to our knowledge, there was no
concurrent local or regional intervention implemented for
CHF management during the study period to account for
our findings. The use of interrupted time-series analysis
also allowed us to adjust for random and seasonal varia-
tions in medication prescription rates, and confirm that
the demonstrated improvements were not merely seasonal
fluctuations. Although there is potential for sample bias,
inclusion of approximately 68% of discharges each quarter
over a period of 3 years and the conservative statistical
analysis techniques used should be sufficient to overcome
the issue of random sampling error.
General medicine has traditionally had few clinical indi-
cators to support quality practice. The prescription rates
of beta-blockers and ACEI/ARB for patients admitted
with CHF is a prime candidate given CHF is a common
cause of hospitalisation, has high mortality and morbidity,
with clear evidence for improved outcomes with these
medications. The Australian Council on Healthcare Stan-
dards (ACHS) has recently recommended this indicator as
a potential measure of the quality use of medications,
however widespread reporting has been limited and it is
unclear to what extent it is being monitored within indi-
vidual health services [35]. The findings of our study
would support progressing the use of this indicator within
hospitals and give evidence for how it might be translated
into improved practice.
Conclusions
In this study, implementation of a structured education
program and regular performance feedback was feasible,
and associated with durable improvements in appropri-
ate prescribing for CHF with a corresponding decrease
in CHF related readmissions. These findings support the
more widespread use of these interventions to improve
the management of patients admitted with CHF.
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